Vical Incorporated At Credit Suisse Group Healthcare Conference Call Transcript

Vical Incorporated (VICL)

Credit Suisse Group Healthcare Conference Call Transcript

November 9, 2011 9:30 AM ET

Executives

Adam Cutler – Senior Biotechnology Analyst, Credit Suisse

Vijay Samant – President & Chief Executive Officer

Presentation

Adam Cutler

Compare to:
Previous Statements by VICL
» Vical Incorporated's CEO Discusses Q3 2011 Results - Earnings Call Transcript
» Vical's CEO Discusses Q2 2011 Results - Earnings Call Transcript
» Vical's CEO Discusses Q1 2011 Results - Earnings Call Transcript
» Vical CEO Discusses Q4 2010 Results - Earnings Call Transcript

Good morning everybody. I am Adam Cutler, one of Credit Suisse’s Senior Biotechnology Analyst. It’s my pleasure to introduce our first presenting company of the morning, Vical. Our speaker is Vijay Samant, CEO. Vical is a company we recently launched coverage on, with an exciting pipeline of products, the main one that investors are seem to be focusing on these days is Allovectin, the company’s Phase 3 product for the treatment of metastatic melanoma with data coming next year which should be a very exciting time at Vical. So, I will let Vijay tell you more about it. Vijay?

Vijay Samant

Thank you, Adam, and thank you to Credit Suisse for inviting us here for this exciting conference in a wonderful location. I thought the temperatures were going to be slightly warmer than other parts of the country, but it’s chilly this morning here.

Before I begin, I want to remind you of the Safe Harbor statement. We will be making some forward-looking statements. So, please refer to our filed SEC documents to fully understand the risk associated in investing in Vical.

The majority of my presentation is going to be focused on Allovectin-7 because this is a major event driver for us in the next six to 12 months. But briefly Vical at a glance, we are a biotechnology company with a broad pipeline. Our lead program is immunotherapy for treatment of melanoma. We expect some pivotal data in the second quarter of 2012. The Allovectin program is something that we have been working for a very long time, and it has potential applications to other solid tumor cancer such as head and neck.

1 2 3 Next › Last »